Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of FLNA, FBLN1 and TSP-1 as markers in preparation of asbestos-related disease detection kit

A technology of TSP-1 and FBLN1, applied in the field of biomedicine, can solve problems such as limited application, no MM serum proteomics report, insufficient sensitivity or specificity, etc., and achieve high sensitivity and high diagnostic value

Pending Publication Date: 2021-04-09
ZHEJIANG MEDICAL COLLEGE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although many biomarkers have been proposed for the diagnosis of malignant mesothelioma, such as hyaluronic acid, soluble mesothelin-related protein, osteopontin, megakaryocyte-promoting factor, fibulin-3, serum high mobility group protein B1, etc. , but there are many problems with insufficient sensitivity or specificity, and it still needs to be verified in large-sample population studies, which limits its clinical application
However, there are no reports of iTRAQ-based MM serum proteomics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of FLNA, FBLN1 and TSP-1 as markers in preparation of asbestos-related disease detection kit
  • Application of FLNA, FBLN1 and TSP-1 as markers in preparation of asbestos-related disease detection kit
  • Application of FLNA, FBLN1 and TSP-1 as markers in preparation of asbestos-related disease detection kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] This embodiment provides a method for screening differential proteins in malignant mesothelioma serum based on iTRAQ technology, and in this embodiment, further identification and verification analysis of the screened differential proteins is carried out to determine the screened differential proteins as Feasibility of diagnostic biomarkers for malignant mesothelioma. The specific scheme content of this embodiment is as follows:

[0043] 1. Materials and methods

[0044] 1. Study Objects and Sample Collection

[0045] The research subjects of this project were selected from an asbestos processing area with a long history in Zhejiang Province. A total of 176 cases were collected from 2014 to 2017 and divided into the following six groups: (1) 40 cases of healthy control group: no clear history of asbestos exposure and Chest X-ray examination showed normal; (2) Asbestos exposure less than 10 years group (AE<10Y) 42 cases: occupational exposure to asbestos less than 10 y...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of FLNA, FBLN1 and TSP1 as markers in preparation of an asbestos-related disease detection kit, and belongs to the technical field of biomedicine. Serum differential proteins Filamin A (FLNA), Fibulin-1 (FBLN1) and Thrombospondin-1 (TSP-1) are screened out based on iTRAQ and through a 2D LC-MS / MS technology, it is further verified that the FLNA, FBLN1 and TSP-1 can serve as potential biomarkers for malignant mesothelioma diagnosis and have high sensitivity and specificity; the FBLN1 and TSP-1 have high clinic application value when serving as potential biomarkers for lung joint diagnosis. When applied to multi-index joint use, the FLNA, FBLN1 and TSP-1 have higher diagnostic value.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of FLNA, FBLN1 and TSP-1 as biomarkers in the preparation of diagnostic kits for asbestos-related diseases such as malignant mesothelioma and asbestosis. Background technique [0002] Malignant mesothelioma (MM) is a relatively rare and highly invasive tumor closely related to asbestos exposure. wait. The disease has an insidious onset and lacks specific clinical manifestations. Most patients are diagnosed at an advanced stage, and there is currently no effective treatment plan. The prognosis is very poor, and the median survival time is generally less than one year. The average potential years of life lost (PYLL) for malignant mesothelioma is 17 years. Due to the long incubation period (20-40 years) and the continuous use of asbestos in some countries, the annual death toll from malignant mesothelioma is still increasing globally, and the corresponding soci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/68G01N30/02G01N30/06G01N30/34G01N30/36G01N30/72G01N30/88
CPCG01N33/57488G01N33/57407G01N33/6884G01N30/02G01N30/06G01N30/34G01N30/36G01N30/7233G01N30/88G01N2030/8831G01N2800/12
Inventor 楼建林夏海玲冯玲芳蒋兆强余珉王晶陈钧强张幸
Owner ZHEJIANG MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com